TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06730126: Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$759,000

Rescue Site Savings

+$517,500

Unlock Full NCT06730126 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06730126 Rescue Dossier →